Compare Abeona Therapeutics Inc (ABEO) vs Shell PLC (SHEL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Shell PLC — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while Shell PLC trades at $82.06 (market cap $220.29B). The key difference: Shell PLC is far larger — about 590.1× Abeona Therapeutics Inc's market cap, and Shell PLC pays a 3.81% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | SHEL | |
|---|---|---|
Market Cap | $373.32M | $220.29B |
Sector | Health | Energy |
52-Week High | $7.23 | $94.15 |
52-Week Low | $4.17 | $70.28 |
Enterprise Value | $228.22M | $272.82B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Shell (SHEL) trades at $81.99, up 5.09% on the day, with strong analyst support showing 69% buy ratings and a $112.10 consensus price target. The stock shows attractive valuation metrics with P/E of 12.17 and P/S of 0.86, while recent Q1 2026 earnings beat expectations. However, technical indicators signal bearish momentum despite positive news about stronger gas trading performance and improved refining margins ahead of Q2 results.
Shell presents a compelling value opportunity with solid profitability (7.01% net margin) and strong cash flow generation, though faces headwinds from declining revenue trends and geopolitical risks affecting production. The company's strategic focus on LNG growth and portfolio optimization supports long-term prospects, but investors should monitor execution risks and oil price volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Shell PLC
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →
